2,501
Views
63
CrossRef citations to date
0
Altmetric
Original Articles

Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies

, , , , , & show all
Pages 1-6 | Received 07 Aug 2015, Accepted 08 Dec 2015, Published online: 25 Jan 2019

  • LivermoreDM.Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?Clin Infect Dis2002; 34:634–640.
  • GaynesR,EdwardsJR.Overview of nosocomial infections caused by gram-negative bacilli.Clin Infect Dis2005; 41:848–854.
  • BodeyGP,JadejaL,EltingL.Pseudomonas bacteremia. Retrospective analysis of 410 episodes.Arch Intern Med1985; 145:1621–1629.
  • ChatzinikolaouI,Abi-SaidD,BodeyGPet al.Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes.Arch Intern Med2000; 160:501–509.
  • HilfM,YuVL,SharpJet al.Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.Am J Med1989; 87:540–546.
  • AlikhaniMY,Karimi TabarZ,MihaniFet al.Antimicrobial resistance patterns and prevalence of blaPER-1 and blaVEB-1 genes among ESBL-producing Pseudomonas aeruginosa isolates in west of Iran.Jundishapur J Microbiol2014; 7:e8888.
  • MoralesE,CotsF,SalaMet al.Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition.BMC Health Serv Res2012; 12:122.
  • McGowanJEJr.Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.Am J Infect Control2006; 34:S29–S37discussion S64–S73.
  • YanagiharaK,KadotaJ,AokiNet al.Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: General view of the pathogens' antibacterial susceptibility.J Infect Chemother2015; 21:410–420.
  • ObritschMD,FishDN,MacLarenRet al.National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.Antimicrob Agents Chemother2004; 48:4606–4610.
  • AcarJF.Consequences of bacterial resistance to antibiotics in medical practice.Clin Infect Dis1997; 24(Suppl 1):S17–S18.
  • FalagasME,TansarliGS,KarageorgopoulosDEet al.Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.Emerg Infect Dis2014; 20:1170–1175.
  • DiazGranadosCA,ZimmerSM,KleinMet al.Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis.Clin Infect Dis2005; 41:327–333.
  • SuarezC,PenaC,GavaldaLet al.Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.Int J Infect Dis2010; 14:e73–e78.
  • LautenbachE,SynnestvedtM,WeinerMGet al.Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes.Infect Control Hosp Epidemiol2010; 31:47–53.
  • PenaC,SuarezC,GozaloMet al.Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.Antimicrob Agents Chemother2012; 56:1265–1272.
  • KangCI,KimSH,ParkWBet al.Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.Microb Drug Resist2005; 11:68–74.
  • DantasRC,FerreiraML,Gontijo-FilhoPPet al.Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.J Med Microbiol2014; 63:1679–1687.
  • JooEJ,KangCI,HaYEet al.Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.Microb Drug Resist2011; 17:305–312.
  • KrcmeryJrV,TruplJ,KunovaAet al.Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome.Bratisl Lek Listy1996; 97:647–651.
  • StangA.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.Eur J Epidemiol2010; 25:603–605.
  • YangWS,VaP,WongMYet al.Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies.Am J Clin Nutr2011; 94:1575–1583.
  • YangY,ZhangD,FengNet al.Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis.Gastroenterology2014; 147:1031–1042.
  • ZhangY,ZhengQJ,WangSet al.Diabetes mellitus is associated with increased risk of surgical site infections: A meta-analysis of prospective cohort studies.Am J Infect Control2015; 43:810–815.
  • GuWJ,WangF,TangLet al.Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies.Chest2015; 147:335–346.
  • OwnbyRL,CroccoE,AcevedoAet al.Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.Arch Gen Psychiatry2006; 63:530–538.
  • LoCK,MertzD,LoebM.Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments.BMC Med Res Methodol2014; 14:45.
  • LarssonSC,OrsiniN,WolkA.Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies.JAMA2010; 303:1077–1083.
  • HigginsJP,ThompsonSG.Quantifying heterogeneity in a meta-analysis.Stat Med2002; 21:1539–1558.
  • HigginsJP,ThompsonSG,DeeksJJet al.Measuring inconsistency in meta-analyses.BMJ2003; 327:557–560.
  • DerSimonianR,LairdN.Meta-analysis in clinical trials.Control Clin Trials1986; 7:177–188.
  • HarbordRM,EggerM,SterneJA.A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints.Stat Med2006; 25:3443–3457.
  • SterneJA,EggerM.Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.J Clin Epidemiol2001; 54:1046–1055.
  • CosgroveSE,CarmeliY.The impact of antimicrobial resistance on health and economic outcomes.Clin Infect Dis2003; 36:1433–1437.
  • CosgroveSE.The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs.Clin Infect Dis2006; 42:S82–S89.
  • LevinAS,BaroneAA,PencoJet al.Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.Clin Infect Dis1999; 28:1008–1011.
  • RodmanDP,McKnightJT,RogersTet al.The appropriateness of initial vancomycin dosing.J Fam Pract1994; 38:473–477.
  • AnderssonDI.The biological cost of mutational antibiotic resistance: any practical conclusions?Curr Opin Microbiol2006; 9:461–465.
  • Giamarellos-BourboulisEJ,PlachourasD,TzivraAet al.Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study.Clin Exp Immunol2004; 135:240–246.